DEKA Biosciences announced as a Prix Galien Nominee
-- In Partnership with Business France, Awards will be presented on October 27, 2022, at the Prix Galien USA Awards Ceremony in New York City
NEW YORK, July 28, 2022 /PRNewswire/ -- The Galien Foundation, the premier global institution dedicated to honoring innovators in life sciences, today announced the 2022 Prix Galien USA Award nominees for "Best Digital Health Solution," "Incubators, Accelerators and Equity," and "Prix Galien Startup." Winners will be announced during the Prix Galien USA Awards Ceremony on October 27, 2022, at the American Museum of Natural History in New York City.
"The Prix Galien Awards have become the most coveted prizes for those who dedicate their lives to the development of meaningful drugs and innovations," said Bernard Poussot, Director, Roche Holding, Former Chairman & CEO, Wyeth, Prix Galien Startup, Digital Health and Incubators, Accelerators and Equity Committee Chairman. "Members of the Awards Committees applaud the unwavering commitment of each nominee in their quest to provide a healthier future for the next generation."
The newest Prix Galien Award category, "Incubators, Accelerators and Equity," acknowledges the role played by these institutions in guiding the next wave of innovators by offering a range of mentoring skills including clinical trial design expertise, legal counsel, lab space, professional development, peer-to-peer support, free access to leading advisors and economic support to advance life science innovation.
"During my 30-year career at Johnson & Johnson, I learned the importance of casting a wide net in pursuing new ideas while taking on the task of turning these into meaningful products for patients," said Alex Gorsky, Executive Chairman, Johnson & Johnson, member of the Prix Galien Startup, Digital Health and Incubators, Accelerators and Equity Committee. "It is an honor to join the Awards jurors responsible for recognizing the industry's very best innovative practices in the new Award category."
Judges will evaluate submissions using seven criteria, including details on how the incubator/accelerator addresses the needs of candidates accepted, background on how success is measured during the incubation, acceleration or funding period, and examples of businesses that have "graduated" or "exited" from the incubator and/or accelerator, alongside a candidate's 800-word entry.
"At Alexandria, we are immensely proud to play an essential role in catalyzing life science entrepreneurship and innovation as well as the growth of life science ecosystems through our one-of-kind, best-in-class Alexandria LaunchLabs® life science startup platform. We curate and coalesce mission-critical real estate, early-stage risk capital, mentorship and company-building resources to accelerate the translation of scientific discoveries into new treatments and cures to help meet society's significant unmet medical need," said Joel S. Marcus, J.D., CPA, Executive Chairman & Founder, Alexandria Real Estate Equities, Inc./Alexandria Venture Investments. "I am honored to join the Prix Galien's esteemed Award jury, and with the creation of this new Award category, The Galien Foundation is once again positioned at the forefront of endeavors that will help advance progress toward medicines to improve, extend and save the lives of patients around the world."
The "Best Digital Health Solution" category recognizes excellence in research and development that has significantly improved the human condition. The "Prix Galien Startup" category, which rewards and supports innovation worldwide, will announce three winners for, "Best Startup in Pharmaceutical or Biotechnology Industry," "Best Startup in in the Medical Technologies Industry," and "Best Startup in the Digital Health Industry." Frederic Rossi, General Manager Business France for North America underlines the "tremendous opportunity for French companies to present astonishing projects and to meet with US healthcare leaders for the rapid adoption of essential innovations."
Read more here